Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for ovarian cancer, familial, susceptibility to, 2 has been reported in the published literature.
No clinical trials have been registered for ovarian cancer, familial, susceptibility to, 2.
165 publications have been identified in PubMed for ovarian cancer, familial, susceptibility to, 2. Kisho has analyzed 103 by research type. Research spans Epidemiology / Natural History (32%), Review / Meta-Analysis (20%), and Diagnostic / Biomarker (18%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 33 | 32% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 12:30 PM UTC
Research summaries |
21 |
20% |
Testing and diagnosis research | 19 | 18% |
Laboratory research | 17 | 17% |
Clinical study results | 11 | 11% |
New treatment approaches | 2 | 2% |
Bancroft EK (2026). [PMID: 41714267](https://pubmed.ncbi.nlm.nih.gov/41714267/). *Eur Urol*. [Diagnostic / Biomarker]
Viveros-Carreño D (2026). [PMID: 42056783](https://pubmed.ncbi.nlm.nih.gov/42056783/). *Int J Gynecol Cancer*. [Review / Meta-Analysis]
Cheng HH (2026). [PMID: 41671423](https://pubmed.ncbi.nlm.nih.gov/41671423/). *J Natl Compr Canc Netw*. [Review / Meta-Analysis]
Duranti S (2026). [PMID: 42130632](https://pubmed.ncbi.nlm.nih.gov/42130632/). *Front Oncol*. [Review / Meta-Analysis]
Gandhi A (2026). [PMID: 41637687](https://pubmed.ncbi.nlm.nih.gov/41637687/). *J Clin Oncol*. [Clinical Trial Publication]
Calzone K (2026). [PMID: 41846226](https://pubmed.ncbi.nlm.nih.gov/41846226/). *Semin Oncol Nurs*. [Review / Meta-Analysis]
Billaud A (2026). [PMID: 41223770](https://pubmed.ncbi.nlm.nih.gov/41223770/). *Breast*. [Review / Meta-Analysis]
Campoy S (2026). [PMID: 41389835](https://pubmed.ncbi.nlm.nih.gov/41389835/). *J Natl Cancer Inst*. [Review / Meta-Analysis]
Lee EJ (2026). [PMID: 41943275](https://pubmed.ncbi.nlm.nih.gov/41943275/). *J Korean Med Sci*. [Diagnostic / Biomarker]
Ebata A (2026). [PMID: 41093592](https://pubmed.ncbi.nlm.nih.gov/41093592/). *Tohoku J Exp Med*. [Epidemiology / Natural History]